98%
921
2 minutes
20
The development of bacterial antibiotic resistance poses a danger to healthcare systems worldwide. To reduce the spread of disease, researchers are looking for novel measures to control bacterial infections to reduce the spread of disease. The antibacterial properties of Xanthium strumarium methanolic and ethanolic extracts were evaluated against Enterobacter cloacae and E. hormaeche isolated from some invertebrates (Porcellio laevis, Armadillidium sp. (isopods), and Archispirostreptus syriacus). All Enterobacter strains tested positive for the presence of the virulence genes csgA, csgD, AcrAB, fimH, and Hsp60. Extracts of X. strumarium had significant anti-biofilm activity against E. cloacae and E. hormaechei. The disruption of established biofilm growth by the plant samples proved to be effective against E. cloacae and E. hormaechei. Both E. cloacae and E. hormaechei showed inhibition of biofilm formation and promotion of biofilm eradication in response to X. strumarium extract. Phenolic compounds such as ferulic acid, chlorogenic acid, and trans-cinnamic acid, and flavonoids such as kaempferol were the most abundant components in the extract and might play crucial roles in the extract's antibacterial and antibiofilm action. Results suggest that ethanolic leaf extracts from X. strumarium show potential as a novel approach to prevent infections caused by E. cloacae and E. hormaechei.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.14715/cmb/2024.70.11.24 | DOI Listing |
Int J Antimicrob Agents
August 2025
Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China. Electronic address:
Objective: This study aims to systematically investigate the molecular epidemiology and genomic characteristics of Enterobacter cloacae complex (ECC) strains globally harboring bla and mcr, as well as the co-existence of drug resistance genes. The goal is to provide insights and recommendations for monitoring clinical drug-resistant strains and super-resistant plasmids.
Methods: This study analyzed 281 ECC isolates harboring both bla and mcr, obtained from NCBI GenBank database (2003-2024) with whole-genome sequencing data.
Microbiol Resour Announc
August 2025
Department of Medical Microbiology, Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
is an emerging gram-negative bacterium belonging to the complex. Here, we present the draft genome sequence of the HKEH-1 strain isolated from a blood sample from a type II diabetic patient, harboring three plasmids which share high homology to known plasmids of the species.
View Article and Find Full Text PDFJ Glob Antimicrob Resist
July 2025
Antimicrobial Resistance and Microbial Ecology Group, School of Medicine, University of Galway, Galway, Ireland. Electronic address:
Objectives: Antimicrobial resistance (AMR) is a global health concern related to antimicrobial use and the subsequent emergence of resistant organisms, including carbapenemase-producing Enterobacterales (CPE). CPE isolate co-carrying bla and mcr-9.1 have been scarcely reported internationally.
View Article and Find Full Text PDFMed Microbiol Immunol
July 2025
Bacteriophage Laboratory, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114, Wroclaw, Poland.
The Enterobacter cloacae complex (ECC) is a prevalent nosocomial pathogen associated with various human infections, which currently comprises several species, including Enterobacter cloacae and Enterobacter hormaechei. Strains capable of producing biofilm on various biotic and abiotic surfaces pose a particular threat. Therefore, we focused on three E.
View Article and Find Full Text PDFMicrobiol Spectr
July 2025
Department of Internal Medicine, College of Medicine, National Cheng Kung University, National Cheng Kung University Hospital, Tainan, Taiwan.
Carbapenem-resistant complex (ECC) has become a clinically important pathogen with increased incidence worldwide in recent years. In Taiwan, IMP-8 accounted for most carbapenemase produced by ECC in earlier studies. Clinical ECC isolates resistant to ertapenem, imipenem, and meropenem at the study hospital between 2014 and 2022 were collected at a medical center in southern Taiwan.
View Article and Find Full Text PDF